CSL has patented a method for reducing hospitalization risk due to respiratory illness in elderly individuals by administering an adjuvanted influenza vaccine. The vaccine, containing a squalene-containing oil-in-water emulsion, significantly lowers hospitalization rates compared to unadjuvanted vaccines, especially in those receiving immunosuppressive therapy. GlobalData’s report on CSL gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights CSL Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on CSL, Personalized cancer vaccines was a key innovation area identified from patents. CSL's grant share as of February 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11896660B1) outlines a method aimed at reducing the incidence of hospitalization for influenza respiratory illness in elderly individuals. The method involves administering a priming, first dose of a tetravalent influenza vaccine adjuvanted with a squalene-containing oil-in-water emulsion to elderly subjects aged between 65-100 years who are receiving immunosuppressive therapy. This approach is designed to lower the hospitalization rates for influenza respiratory illness compared to elderly subjects who receive an unadjuvanted influenza vaccine. Importantly, the recipients of the adjuvanted vaccine do not receive an unadjuvanted vaccine during consecutive influenza seasons.

The patent further specifies details regarding the composition of the emulsion, with the emulsion containing squalene, a tocopherol, and polysorbate 80, and having submicron oil droplets with specific average diameters. The adjuvanted tetravalent influenza vaccine can be either a split virus antigen vaccine or a purified surface antigen vaccine, administered intramuscularly. Additionally, the concentration of squalene in the oil-in-water emulsion is highlighted as a critical factor in the method's efficacy, ranging from 2 to 10% by weight. The patent also discusses the potential for administering a second booster dose of the adjuvanted vaccine, providing a comprehensive overview of the method's application and potential impact on reducing influenza-related hospitalizations in the elderly population.

To know more about GlobalData’s detailed insights on CSL, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies